Showing results (591-600 of 2,688) with videos related to

Sort By:
Pageof 269
The Lancet. Infectious Diseases|June 16, 2024
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trialSarah E Silk, Wilmina F Kalinga, Jo Salkeld, et al.
The Lancet. Infectious Diseases|October 20, 2023
Impact of piperaquine resistance in Plasmodium falciparum on malaria treatment effectiveness in The Guianas: a descriptive epidemiological studyCelia Florimond, Franck de Laval, Angela M Early, et al.
The Lancet. Infectious Diseases|April 14, 2024
An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trialKatrina M Pollock, Álvaro H Borges, Hannah M Cheeseman, et al.
The Lancet. Infectious Diseases|March 22, 2024
Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trialAvika Dixit, Richard Bennett, Kashif Ali, et al.
The Lancet. Infectious Diseases|March 23, 2024
Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UKShamez N Ladhani, Peter J White, Helen Campbell, et al.
The Lancet. Infectious Diseases|September 3, 2023
Evaluation of a point-of-care test for the diagnosis of Taenia solium neurocysticercosis in rural southern Tanzania: a diagnostic accuracy studyDominik Stelzle, Charles E Makasi, Veronika Schmidt, et al.
The Lancet. Infectious Diseases|September 8, 2023
Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patientsBenjamin W Teh, Malgorzata Mikulska, Dina Averbuch, et al.
The Lancet. Infectious Diseases|September 3, 2023
Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trialRituparna Das, Daniel Blázquez-Gamero, David I Bernstein, et al.
The Lancet. Infectious Diseases|September 3, 2023
Antimicrobial treatment imprecision: an outcome-based model to close the data-to-action loopAlex Howard, Nada Reza, Stephen Aston, et al.
The Lancet. Infectious Diseases|August 24, 2023
Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trialBruno Maranda, Sébastien M Labbé, Magali Lurquin, et al.
Pageof 269